Considerations for lipid lowering therapy

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

The speaker, as a trained medical professional, observed that his LDL levels were significantly higher when he followed a strict carnivore diet. Although his LDL remains above the reference range, he debated the need for statin therapy, acknowledging that lipid lowering therapy may be appropriate for individuals with monogenic FH, diabetes, or those unwilling to change their diet. However, the speaker also suggested that there is a strong case to consider avoiding lipid lowering therapy for individuals with different contexts, particularly those who are insulin sensitive.

Today, Paul has Dave Feldman on the podcast to discuss, in depth, a recent study that he conducted about LDL and cardiovascular risk and what this may mean for the future of medicine.

*Produced by Mountain Valley Media

00:03:30 The genesis of Dave’s most recent study

00:07:00 is FH a phenotype or genotype polygenetic vs monogenetic

00:22:30 Dave’s overall perspective while conducting studies

0:24:00 Diving into Dave Feldman’s most recent study: Does APOE-B cause atherosclerosis

00:42:30 How the medical community has received this study

00:46:30 Do credentials matter?

00:58:30 Thoughts on Statins

01:04:45 What alters lipid levels

01:13:30 Connect with Dave

References:

Twitter: @realdavefeldman